PATENT CLAIM ANALYSIS

Application Number: 16210492
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "279000"]

Abstract:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Claim (Index 3):
A compound represented by Formula (Va) or (Vb), or a pharmaceutically acceptable salt thereof, wherein:\n X 2  at each occurrence is independently selected from hydrogen or halogen; \n W is selected from the group consisting of hydrogen, halogen, \u2014CN, \u2014N 3 , \u2014OR 11 , \u2014CR 11 R 12 R 3 , \u2014NR 11 R 12 , protected hydroxy, protected amino, optionally substituted \u2014C 1 -C 8  alkyl, optionally substituted \u2014C 2 -C 8  alkenyl, optionally substituted \u2014C 2 -C 8  alkynyl, optionally substituted \u2014C 3 -C 8  cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, \u2014C(O)R 11 , \u2014C(O)OR 11 , \u2014C(O)NR 11 R 12 , \u2014NR 11 CONR 11 R 12 , \u2014S(O) 2 R 11 , \u2014S(O) 2 NR 11 R 12 , \u2014NR 11 S(O) 2 R 12 , \u2014NR 11 S(O) 2 NR 11 R 12 , \u2014P(O)(OR 11 ) 2 , and \u2014NR 11 P(O)(OR 11 ) 2 ; \n R 3  is selected from the group consisting of hydrogen, optionally substituted \u2014C 1 -C 8  alkyl, optionally substituted \u2014C 2 -C 8  alkenyl, optionally substituted \u2014C 2 -C 8  alkynyl, optionally substituted \u2014C 3 -C 8  cycloalkyl, \u2014CN, \u2014OR 11 , and \u2014NR 11 R 12 ; R 4  is selected from the group consisting of \u2014NR 11 R 12 , OR 11 , optionally substituted \u2014C 1 -C 8  alkyl, optionally substituted \u2014C 2 -C 8  alkenyl, optionally substituted \u2014C 2 -C 8  alkynyl, optionally substituted \u2014C 3 -C 8  cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; \n R 15  is hydrogen, halo, CN, \u2014NR 11 R 12 , \u2014N 3 , optionally substituted \u2014C 1 -C 8  alkyl, optionally substituted \u2014C 2 -C 8  alkenyl, optionally substituted \u2014C 2 -C 8  alkynyl, optionally substituted \u2014C 3 -C 8  cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; and \n R 11  and R 12  at each occurrence are independently selected from the group consisting of hydrogen, optionally substituted \u2014C 1 -C 8  alkyl, optionally substituted \u2014C 2 -C 8  alkenyl, optionally substituted \u2014C 2 -C 8  alkynyl, optionally substituted \u2014C 3 -C 8  cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 98.0
- Lexical Diversity: 1.72131
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16210472', '15209150', '15421777', '15216124', '15088517']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8289927996961702
- 35 USC 102 Novelty (BERT): 0.5739483009326206
- Combined Prediction Score: 0.8034883498198153
- Mean Citation Score: 404.732338
- Max Citation Score: 427.52896
- Similarity Product: 383.5889671607971

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test